Alambic Investment Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Alambic Investment Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,325	Closed	-$244K	–	384
2018 Q3	$244K	Sell	11,325 -29,452	-72%	-$896K	0.19%	186
2018 Q2	$1.75M	Buy	40,777 +34,899	+594%	+$1.6M	0.48%	65
2018 Q1	$384K	Buy	+5,878	New	+$416K	0.05%	347
2017 Q4	–	Sell	-11,708	Closed	-$1.07M	–	521
2017 Q3	$1.07M	Buy	+11,708	New	+$898K	0.12%	259

Other funds holding LUMO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alambic Investment Management's LUMO Position: Q4 2018 in Review

Alambic Investment Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2018, closing a stake of 11,325 shares — an estimated $244K sold.

Alambic Investment Management first reported a position in LUMO in Q3 2017 and held it in 4 quarters. The position peaked at $1.75M in Q2 2018. 87 funds tracked by Wall St. Rank hold LUMO as of Q4 2018.

Alambic Investment Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Alambic Investment Management sold 11,325 Lumos Pharma, Inc. Common Stock shares in Q4 2018, an estimated $244K.
Alambic Investment Management first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
Alambic Investment Management's Lumos Pharma, Inc. Common Stock position peaked at $1.75M in Q2 2018.
87 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.